Synlogic 停止运营，停止 PKU 治疗试验，并计划评估战略选择，包括潜在的出售或解散。 Synlogic ceases operations, halts PKU treatment trial, and plans to evaluate strategic options, including a potential sale or dissolution.

生物制药公司 Synlogic 宣布将停止运营并停止苯丙酮尿症 (PKU) 治疗的临床试验。 Synlogic, a biopharmaceutical company, announced it would cease operations and halt a clinical trial for phenylketonuria (PKU) treatment. 做出该决定后，该公司股价下跌 55%，至 1.56 美元。 Following the decision, the company's shares fell 55% to $1.56. Synlogic 现在计划评估战略选择，包括潜在的出售或解散。 Synlogic now plans to evaluate strategic options, including potential sale or dissolution. 该公司将裁员 90%，首席执行官奥伊夫·布伦南 (Aoife Brennan) 将离职。 The company will lay off 90% of its workforce and CEO Aoife Brennan will leave. 该决定并非基于安全性或耐受性问题，而是基于内部审查表明该试验不太可能达到其主要终点。 The decision was not based on safety or tolerability concerns, but on an internal review indicating the trial was unlikely to meet its primary endpoint.